Wednesday, February 25, 2026
Fresenius extends CEO Michael Sen’s contract to 2031, appoints Pawlu to the Management Board
Fresenius SE & Co. KGaA’s Supervisory Board has extended the contract of Chief Executive Officer Michael Sen by five years ahead of schedule. The 57-year-old’s contract will now run until 2031.
According to the company, the decision is intended to ensure continuity at the top as Fresenius continues executing its strategic program. Sen has been CEO since October 1, 2022 and also serves as Chairman of the Supervisory Board of listed Fresenius Medical Care.
Christian Pawlu to take Helios responsibility on the Management Board
Effective July 1, 2026, Fresenius will appoint Dr. med. Christian Pawlu to the Management Board. The 48-year-old will be responsible for Fresenius Helios, including Helios hospitals in Germany and Spain-based private hospital group Quirónsalud.
Pawlu will succeed Robert Möller in the Management Board role. Fresenius said Möller will focus on setting up an executive office in Berlin and Brussels going forward.
Background of Sen and Pawlu
- Michael Sen joined Fresenius in April 2021, initially as CEO of Fresenius Kabi. Previously, he served on Siemens AG’s Managing Board and earlier was CFO at E.ON.
- Christian Pawlu has been COO at Helios in Germany since March 2025 and has served as COO for the Fresenius Helios business segment since September 2025. Before that, he led Corporate Development at Fresenius and previously held roles at Sandoz, as CEO of a tech start-up, and as a partner at McKinsey & Company.
Related articles
Roche appoints Mark Dawson to lead pRED
Roche names Mark Dawson as Head of Pharma Research and Early Development from 1 May 2026 and adds him to the Enlarged Corporate Executive Committee.
L’Oréal appoints Julia Huhn to lead communications across DACH
Julia Huhn has led Communication & Public Affairs at L’Oréal DACH since 15 February. She succeeds Stefan Geister and joins from Santander.
Linda Maria Diodati appointed Managing Director at Thieme Media
Linda Maria Diodati became Managing Director of Thieme Media on 1 February 2026. She succeeds Oliver Fock, who moved into a staff role.
Biogen names Dr. Maria C. Freire as next board chair
Biogen will shift its board leadership: Dr. Maria C. Freire is set to become chair after the June 9, 2026 annual meeting.
Sanofi appoints Belén Garijo as new CEO
Sanofi has appointed Belén Garijo as CEO. Paul Hudson will leave on Feb. 17, 2026, with Olivier Charmeil serving as interim leader.
Engelhard strengthens strategic development with new CCSO role
Engelhard has created a Transformation Office and appointed Ann-Katrin Frank as Chief Commercial Strategy Officer to steer strategic development.
Daiichi Sankyo Appoints New Leadership for European Research Center
Daiichi Sankyo has appointed Dr. Veronika Rozehnal as the new Head of the Translational Research Center Europe. She succeeds Dr. Jürgen Müller, who is retiring after nearly 30 years of research service.
New employee representative on the Board of Directors of Novo Nordisk
After 22 years at Novo Nordisk, Thomas Rantzau steps down from the Board of Directors. His former alternate, Tanja Villumsen, assumes the role of employee representative with immediate effect.